MU Investments Co. Ltd. cut its stake in shares of United Therapeutics Corp. (NASDAQ:UTHR) by 39.8% during the second quarter, Holdings Channel reports. The institutional investor owned 1,060 shares of the biotechnology company’s stock after selling 700 shares during the period. MU Investments Co. Ltd.’s holdings in United Therapeutics Corp. were worth $110,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in UTHR. Daiwa Securities Group Inc. increased its stake in United Therapeutics Corp. by 16.7% in the second quarter. Daiwa Securities Group Inc. now owns 1,050 shares of the biotechnology company’s stock worth $111,000 after buying an additional 150 shares in the last quarter. Nordea Investment Management AB boosted its position in United Therapeutics Corp. by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock worth $128,000 after buying an additional 190 shares during the last quarter. Eqis Capital Management Inc. acquired a new position in United Therapeutics Corp. during the second quarter worth approximately $254,000. Creative Planning boosted its position in United Therapeutics Corp. by 330.4% in the second quarter. Creative Planning now owns 2,410 shares of the biotechnology company’s stock worth $255,000 after buying an additional 1,850 shares during the last quarter. Finally, Acrospire Investment Management LLC acquired a new position in United Therapeutics Corp. during the first quarter worth approximately $267,000.
United Therapeutics Corp. (NASDAQ:UTHR) traded up 2.66% during midday trading on Friday, hitting $118.08. 738,654 shares of the stock were exchanged. United Therapeutics Corp. has a 1-year low of $97.52 and a 1-year high of $164.04. The firm has a market capitalization of $5.13 billion, a P/E ratio of 5.71 and a beta of 1.46. The firm’s 50-day moving average price is $123.53 and its 200 day moving average price is $115.94.
United Therapeutics Corp. (NASDAQ:UTHR) last posted its quarterly earnings data on Thursday, July 28th. The biotechnology company reported $4.55 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.22 by $1.33. The firm earned $412.60 million during the quarter, compared to analyst estimates of $395.15 million. United Therapeutics Corp. had a net margin of 64.26% and a return on equity of 49.30%. The company’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same quarter last year, the business posted $2.55 EPS. Analysts expect that United Therapeutics Corp. will post $15.82 earnings per share for the current fiscal year.
UTHR has been the subject of a number of research analyst reports. Cowen and Company reiterated a “buy” rating and set a $144.00 price target on shares of United Therapeutics Corp. in a report on Friday, September 23rd. Zacks Investment Research upgraded United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $137.00 price target for the company in a report on Wednesday. Argus reiterated a “hold” rating on shares of United Therapeutics Corp. in a report on Tuesday, August 23rd. HC Wainwright cut United Therapeutics Corp. from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $175.00 to $95.00 in a report on Wednesday, June 15th. Finally, Wedbush reiterated an “outperform” rating and set a $229.00 price target on shares of United Therapeutics Corp. in a report on Thursday, July 28th. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $137.09.
In other news, Director Christopher Patusky sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $122.73, for a total transaction of $613,650.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $613,650. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,293 shares of the stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $109.87, for a total transaction of $142,061.91. Following the transaction, the chief executive officer now directly owns 1,433 shares of the company’s stock, valued at $157,443.71. The disclosure for this sale can be found here. 7.50% of the stock is currently owned by company insiders.
About United Therapeutics Corp.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corp. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.